|
Goldman Sachs Analysts Question Whether Curing Patients Is Good for Business
h/t Instapundit[Gizmodo] Recent advancements in science and medicine have put cures within reach for diseases that have long plagued humankind. In a recent report, though, Goldman Sachs analysts posed an uncomfortable question that quickly sparked criticism. "Is curing patients a sustainable business model?" analysts asked in an April 10 report entitled "The Genome Revolution," which CNBC first reported. One-and-done cures enabled by gene editing, analyst Salveen Richter wrote in the note to clients this week, are near-miraculous innovations that stand to benefit patients immensely. But they also present a challenge to business. "While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow," she wrote. Posted by: g(r)omgoru 2018-04-17 |
| http://www.rantburg.com/poparticle.php?ID=512627 |